Adamas Announces Data Presentations at the 71st American Academy of Neurology Annual Meeting
"New data from our two-year open label study suggest chronic GOCOVRI treatment may enable the dose of dopaminergic medications to be modified with an improvement in OFF and dyskinesia. We hope these data, coupled with the GOCOVRI pivotal program, can provide confidence to neurologists to increase the use of dopaminergic therapies alongside adjunctive GOCOVRI to benefit their PD patients," said
Details of the poster presentations are below:
GOCOVRI Poster Presentation
Title: Changes to Levodopa Daily Dose in Parkinson’s Disease (PD) Patients with Dyskinesia While on GOCOVRITM (amantadine) Extended Release Capsules: A Two-Year Phase 3 Open Label Study Analysis
Poster ID: P4.7-010
Poster Session 4: Movement Disorders ePoster Session
Date and Time:
ADS-5102 Poster Presentation
Title: INROADS: A Phase 3 Study to Assess the Efficacy and Safety of ADS-5102 (amantadine) Extended Release Capsules in Multiple Sclerosis Patients with Walking Impairment
Poster ID: P5.2-087
Poster Session 5: MS Symptom Assessment and Management
Date and Time:
About GOCOVRI QHS
GOCOVRITM (amantadine) extended-release capsules is the first and only
GOCOVRI is thought to work by reducing the amount of glutamate hyperactivity in a region of the brain that controls movement, in patients experiencing dyskinesia and OFF. The NMDA receptor is activated by glutamate and causes post-synaptic nerve signaling in this area of the brain, which is modulated by dopamine. Levodopa therapy replaces dopamine lost in Parkinson’s disease but may result in large fluctuations in synaptic levels of dopamine during waking hours, further exacerbating glutamate hyperactivity. GOCOVRI, developed by Adamas, is novel in that it selectively blocks the NMDA receptor in a time-dependent manner. Taken at bedtime (QHS), GOCOVRI provides an initial lag and a slow rise in amantadine concentration during the night and a high concentration from the morning and throughout the waking day. Additionally, the adjunctive use of GOCOVRI does not require dose changes to dopaminergic therapies. The most common side effects of GOCOVRI include dry mouth, swelling of legs and feet, constipation, and falls.
For more information about GOCOVRI, please see the U.S. Prescribing Information at www.GOCOVRI.com.
Adamas is currently evaluating ADS-5102 in a Phase 3 clinical program for walking impairment in patients with multiple sclerosis. ADS-5102 was previously approved by the
About Adamas Pharmaceuticals, Inc.
Adamas’ goal is to create and commercialize a new generation of medicines intended to lessen the burden of chronic neurologic diseases on patients, caregivers and society using its deep understanding of time-dependent biology. The Company is focused on the commercialization of GOCOVRI™ (amantadine) extended release capsules, the first and only
Vice President, Communications and Engagement
Source: Adamas Pharmaceuticals, Inc.